TABLE 1

Clinical outcomes for sustained responders and late failures over the first 12 months of mepolizumab treatment

	Sustained responders				Late failures
	n	Baseline	12 months	p-value	n	Baseline	12 months	p-value
ACQ	34	2.75 (1.81–4.04)	2.00 (0.83–3.51)	0.003	13	3.83 (2.95–5.08)	3.00 (2.41–4.40)	0.173
AQLQ	31	3.40 (2.20–4.06)	4.73 (3.80–6.20)	<0.001	11	2.07 (1.70–3.80)	3.53 (3.06–4.73)	0.033
FEV₁ % pred	32	73.5 (64.5–85.2)	78.5 (64.0–95.3)	0.651	10	77.0 (59.5–87.3)	67.5 (57.5–84.3)	0.168
F_eNO ppb	28	21.0 (10.3–36.5)	24.0 (9.0–40.8)	0.476	12	34.5 (16.0–58.3)	29 (16.8–85.3)	0.505
Blood eosinophils ×10⁹ cells·L⁻¹	34	0.20 (0.07–0.33)	0.04 (0.02–0.07)	<0.001	10	0.26 (0.11–0.59)	0.06 (0.03–0.13)	0.008
Exacerbations per year	26	4.0 (0.0–5.3)	1.0 (0.0–1.3)	0.006	8	1.0 (0.0–4.0)	1.5 (0.3–2.8)	0.799
Prednisolone dose mg per day	35	10 (5–20)	5 (0–6)	<0.001	13	10 (3–20)	4 (1–11)	0.008
Adherence % pickup	22	80 (80–100)	90 (79–100)	0.876	10	80 (80–85)	80 (80–100)	0.705

Data are presented as median (interquartile range), unless otherwise stated. Significance level (p-value) in change versus baseline by Wilcoxon signed rank test. ACQ: asthma control questionnaire; AQLQ: asthma quality of life questionnaire; FEV₁: forced expiratory volume in 1 s; F_eNO: fractional expired nitric oxide. Baseline blood eosinophils in the table were measured at initiation of treatment, and therefore were not the same as those in the decision for approval of biologic therapy.